Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
Cleveland Clinic · University College London · +28 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,006
total citations
- FWCI
- 112.88
- Percentile
- 100%
- References
- 32
Citations per year
Authors
32- BIBrian I. RiniCorresponding
Cleveland Clinic
- TPThomas Powles
University College London, The Royal Free Hospital, Queen Mary University of London
- MBMichael B. Atkins
Georgetown Lombardi Comprehensive Cancer Center
- BEBernard Escudier
Institut Gustave Roussy
- DFDavid F. McDermott
Beth Israel Deaconess Medical Center
Topics & keywords
Topics
Keywords
- Bevacizumab
- Sunitinib
- Medicine
- Atezolizumab
- Renal cell carcinoma
- Oncology
- Open label
- Internal medicine
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.